Cargando…
The association of body mass index and body composition with plasma amyloid beta levels
Blood-based analysis of amyloid-β is increasingly applied to incrementally establish diagnostic tests for Alzheimer’s disease. To this aim, it is necessary to determine factors that can alter blood-based concentrations of amyloid-β. We cross-sectionally analysed amyloid-β-40 and amyloid-β-42 concent...
Autores principales: | Hermesdorf, Marco, Esselmann, Hermann, Morgado, Barbara, Jahn-Brodmann, Anke, Herrera-Rivero, Marisol, Wiltfang, Jens, Berger, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608109/ https://www.ncbi.nlm.nih.gov/pubmed/37901043 http://dx.doi.org/10.1093/braincomms/fcad263 |
Ejemplares similares
-
Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022) -
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation
por: Klafki, Hans-W., et al.
Publicado: (2022) -
CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006) -
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012) -
Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)